Stay updated on Azacitidine and Pembrolizumab in MDS Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in MDS Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added and notices for Revision: v3.4.1 and the government funding lapse were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the revision label to v3.4.1. The previous revision label v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded: Show glossary; Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4; no study content or endpoints were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page's location information section was updated: 'Texas Locations' was replaced with a general 'Locations' section and a 'Texas' entry added; the 'HHS Vulnerability Disclosure' link was removed, and the page revision advanced from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 appears to be a minor version change and does not alter study details or visible content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Azacitidine and Pembrolizumab in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.